首页> 外文期刊>Biological & pharmaceutical bulletin >Association of ATP-Binding Cassette, Sub-family C, Number 2 (ABCC2) Genotype with Pharmacokinetics of Irinotecan in Japanese Patients with Metastatic Colorectal Cancer Treated with Irinotecan Plus Infusional 5-Fluorouracil/Leucovorin (FOLFIRI)
【24h】

Association of ATP-Binding Cassette, Sub-family C, Number 2 (ABCC2) Genotype with Pharmacokinetics of Irinotecan in Japanese Patients with Metastatic Colorectal Cancer Treated with Irinotecan Plus Infusional 5-Fluorouracil/Leucovorin (FOLFIRI)

机译:用伊立替康联合输注5-氟尿嘧啶/白叶素治疗的日本转移性结直肠癌患者中,ATP结合盒,C亚家族2(ABCC2)基因型与伊立替康的药代动力学相关性

获取原文
获取原文并翻译 | 示例
           

摘要

ATP-binding cassette, sub-family C, number 2 (ABCC2) is involved in the biliary excretion of irinotecan and its metabolites, SN-38 and SN-38 glucuronide. Effects of the ABCC2 genotype on the pharmacokinetics (PK) of irinotecan and the metabolites were examined in Japanese patients with metastatic colorectal cancer receiving irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). ABCC2 genotypes (-1549G>A, -1023G>A, -1019A>G, -24C>T, 1249G>A and 3972C>T) and haplotypes were analyzed for 67 patients with cancer. PK was also examined in a subset of 31 patients receiving FOLFIRI. Relationship between the ABCC2 genotypes or diplotypes and area under the time-concentration curve (AUC) of irinotecan and the metabolites normalized by irinotecan dose was analyzed. The lower AUC of irinotecan was seen in patients with A/A or G/A genotypes at 1249 of the ABCC2 gene than others (p=0.011, Mann-Whitney U teat). AUC of SN-38 in patients with A/A or G/A genotypes at - 1023 was significantly lower than that in others (p=0.018). The haplotype I included -1023A (GAACGC) was the most frequent one with the allele frequency of 0.366. The AUC of SN-38 observed in patients with diplotypes harboring at least one haplotype I was lower than that observed in others (p=0.023). The haplotype IV consisted of 1249 (GGACAC) and was the fourth most frequent one with the allele frequency of 0.127. Patients with diplotypes carrying at least one haplotype IV showed lower AUC of irinotecan than others (p=0.011). Thus, ABCC2 genotype is one of the predictors of the variability of irinotecan PK in Japanese patients with metastatic colorectal cancer receiving FOLFIRI.
机译:ATP结合盒,亚家族C,2号(ABCC2)参与伊立替康及其代谢产物SN-38和SN-38葡糖醛酸的胆汁排泄。在接受伊立替康加5-氟尿嘧啶/亚叶酸钙(FOLFIRI)输注的日本转移性结直肠癌患者中,检查了ABCC2基因型对伊立替康药代动力学(PK)和代谢产物的影响。分析了67例癌症患者的ABCC2基因型(-1549G> A,-1023G> A,-1019A> G,-24C> T,1249G> A和3972C> T)和单倍型。在接受FOLFIRI的31例患者中也检查了PK。分析了伊立替康时间浓度曲线(AUC)下ABCC2基因型或双倍型与面积之间的关系以及通过伊立替康剂量标准化的代谢产物。在ABCC2基因的1249年有A / A或G / A基因型的患者中,伊立替康的AUC较低(p = 0.011,Mann-Whitney U teat)。具有A / A或G / A基因型的患者在1023时SN-38的AUC显着低于其他患者(p = 0.018)。我包括-1023A(GAACGC)的单倍型是最常见的,等位基因频率为0.366。在具有至少一种I型单倍型的双型患者中观察到的SN-38的AUC低于在其他单型中的患者(p = 0.023)。 IV型单倍体由1249(GGACAC)组成,是等位基因频率为0.127的第四高频率单倍体。具有至少一种四倍体型的双倍型患者显示出伊立替康的AUC比其他患者低(p = 0.011)。因此,ABCC2基因型是接受FOLFIRI的日本转移性结直肠癌患者中伊立替康PK变异性的预测指标之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号